Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Solomon

Showing results (1531-1540 of 1,873) with videos related to

Pageof 188
Sort By:
Diabetes, Obesity & Metabolism|January 24, 2019
Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney diseaseDavid M Charytan, Scott D Solomon, Peter Ivanovich, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 2, 2026
Finerenone and eGFR slope across Different Levels of Baseline Albuminuria and Estimated Glomerular Filtration Rate: Insights from FINEARTS-HFFinnian R Mc Causland, Hiddo J L Heerspink, Muthiah Vaduganathan, et al.
American Heart Journal|May 13, 2015
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placeboRhonda Bentley-Lewis, David Aguilar, Matthew C Riddle, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 9, 2009
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Marc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|April 11, 2007
Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema, Donald S Fong, Samara F Strauber, et al.
Journal of the American Medical Informatics Association : JAMIA|December 13, 2024
Effectiveness of electronic medical record-based strategies for death and hospital admission endpoint capture in pragmatic clinical trialsMaryam Rahafrooz, Danne C Elbers, Jay R Gopal, et al.
Journal of the American College of Cardiology|March 27, 2024
Dapagliflozin and Days of Full Health Lost in the DAPA-HF TrialToru Kondo, Ulrik M Mogensen, Atefeh Talebi, et al.
The Science of the Total Environment|June 12, 2010
Evidence needed to manage freshwater ecosystems in a changing climate: turning adaptation principles into practiceR L Wilby, H Orr, G Watts, et al.
Journal of the American Heart Association|December 24, 2024
Clinical Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction and With Reduced Ejection Fraction According to the Prognostic Nutritional Index: Findings From PARADIGM-HF and PARAGON-HFSimone Solano, Mingming Yang, Paolo Tolomeo, et al.
Journal of the American College of Cardiology|November 3, 2024
Finerenone and Kidney Outcomes in Patients With Heart Failure: The FINEARTS-HF TrialFinnian R Mc Causland, Muthiah Vaduganathan, Brian L Claggett, et al.
Pageof 188

Showing results (1531-1540 of 1,873) with videos related to

Sort By:
Pageof 188
Diabetes, Obesity & Metabolism|January 24, 2019
Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney diseaseDavid M Charytan, Scott D Solomon, Peter Ivanovich, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 2, 2026
Finerenone and eGFR slope across Different Levels of Baseline Albuminuria and Estimated Glomerular Filtration Rate: Insights from FINEARTS-HFFinnian R Mc Causland, Hiddo J L Heerspink, Muthiah Vaduganathan, et al.
American Heart Journal|May 13, 2015
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placeboRhonda Bentley-Lewis, David Aguilar, Matthew C Riddle, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 9, 2009
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Marc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|April 11, 2007
Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema, Donald S Fong, Samara F Strauber, et al.
Journal of the American Medical Informatics Association : JAMIA|December 13, 2024
Effectiveness of electronic medical record-based strategies for death and hospital admission endpoint capture in pragmatic clinical trialsMaryam Rahafrooz, Danne C Elbers, Jay R Gopal, et al.
Journal of the American College of Cardiology|March 27, 2024
Dapagliflozin and Days of Full Health Lost in the DAPA-HF TrialToru Kondo, Ulrik M Mogensen, Atefeh Talebi, et al.
The Science of the Total Environment|June 12, 2010
Evidence needed to manage freshwater ecosystems in a changing climate: turning adaptation principles into practiceR L Wilby, H Orr, G Watts, et al.
Journal of the American Heart Association|December 24, 2024
Clinical Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction and With Reduced Ejection Fraction According to the Prognostic Nutritional Index: Findings From PARADIGM-HF and PARAGON-HFSimone Solano, Mingming Yang, Paolo Tolomeo, et al.
Journal of the American College of Cardiology|November 3, 2024
Finerenone and Kidney Outcomes in Patients With Heart Failure: The FINEARTS-HF TrialFinnian R Mc Causland, Muthiah Vaduganathan, Brian L Claggett, et al.
Pageof 188